Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05749939 · ClinicalTrials.gov registry record · Phase 3
Acceptance Commitment Therapy for Caregivers of People with Memory Loss
A Phase 3 study, sponsored by Utah State University.
- Completed
- Registry status
- Phase 3
- Development phase
- 121
- Enrollment target
NCT05749939: Completed Phase 3 study, sponsored by Utah State University.
NCT05749939 is a Phase 3 study that has completed, run by Utah State University. The registered enrollment target is 121 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05749939, a Phase 3 study, has completed, sponsored by Utah State University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 121 participants
- Enrollment target
Study Summary
Family caregivers for persons with dementia report high levels of depression, stress, and burden. Caregivers' limited time, transportation constraints, and unpredictable schedules make on-line, self-guided interventions more accessible and scalable. Acceptance and Commitment Therapy (ACT) is an established and effective in-person therapy, well-suited to the dementia care giving context where caregivers cannot minimize stress exposure, and report difficult thoughts and emotions. ACT for Caregivers is an on-line self-guided ACT intervention that showed effectiveness in a Stage I pilot (n=52) with participants reporting decreased depressive symptoms, stressful reactions to caring, and caregiver burden, and increased quality of life and positive aspects of caring (all p \<.05). Learning from the pilot, the current Stage III intervention will shorten the program from 10 sessions to 6 sessions. The investigators introduce a wait list randomized control trial (RCT) design with fully longitudinal mixed methods to evaluate ACT for Caregivers. Data will be collected at pretest, post-test, and 6-weeks follow-up. Study aims are: 1) to evaluate ACT for Caregivers in a larger sample using an RCT, 2) to understand user experiences and the process of change by collecting short response data from all participants at all time points and interviewing a subset of participants in-depth at two time points, 3) to integrate quantitative and qualitative findings and examine areas of convergence and divergence. This project offers a promising prevention and intervention program to support family caregivers that is scalable, at low cost and with high impact.
Primary Outcome
Group differences between waitlist and treatment group scores after the treatment group has had access to the treatment for 30 days and the waitlist group has not received any intervention for the same amount of time. Caregiver burden is measured by a 12-item \[short\] caregiver burden scale. Participants rate the impact of caregiving on multiple aspects of health (response range 0 never to 4 nearly always). A total possible summed scores range from 0 to 48; higher scores indicate higher burden.
Interventions
- BEHAVIORAL Acceptance and Commitment Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2023-02-16 |
| Est. Completion | 2024-01-21 |
| Phase | Phase 3 |
What the finished NCT05749939 record still lists
NCT05749939 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 1 intervention - of which Acceptance and Commitment Therapy is the first listed.
NCT05749939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05749939 about?
NCT05749939 is a clinical study titled "Acceptance Commitment Therapy for Caregivers of People with Memory Loss". Family caregivers for persons with dementia report high levels of depression, stress, and burden. Caregivers' limited time, transportation constraints, and unpredictable schedules make on-line, self-guided interventions more accessible and scalable. Acceptance and Commitment Therapy (ACT) is an esta...
What is the current status of trial NCT05749939?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 121 participants. The study started on 2023-02-16. Estimated completion is 2024-01-21.
What interventions are being tested in trial NCT05749939?
The interventions under investigation include: Acceptance and Commitment Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT05749939?
This trial is sponsored by Utah State University, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05749939's enrollment target sits among peer trials
121 1619th of 2000 higher than 382 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI